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Liver fibrosis consists in the accumulation of extracellular matrix componentsmainly derived from activated hepatic stellate cells. This is
commonly the result of chronic liver injury repair and represents an important health concern. As liver biopsy is burdened with many
drawbacks, not surprisingly there is great interest to find new reliable noninvasive methods. Among the many are new potential fibrosis
biomarkers under study, some of the most promising represented by the growth arrest-specific gene 6 (Gas6) serum protein and its
family of tyrosine kinase receptors, namely, Tyro3, Axl, and MERTK (TAM). Gas6/TAM system (mainly, Axl and MERTK) has in
fact recently emerged as an important player in the progression of liver fibrosis. This review is aimed at giving an overall perspective
of the roles played by these molecules in major chronic liver diseases. The most promising findings up to date acknowledge that both
Gas6 and its receptor serum levels (such as sAxl and, probably, sMERTK) have been shown to potentially allow for easy and
accurate measurement of hepatic fibrosis progression, also providing indicative parameters of hepatic dysfunction. Although most of
the current scientific evidence is still preliminary and there are no in vivo validation studies on large patient series, it still looks very
promising to imagine a possible future prognostic role for these biomarkers in the multidimensional assessment of a liver patient.
One may also speculate on a potential role for this system targeting (e.g., with small molecule inhibitors against Axl) as a
therapeutic strategy for liver fibrosis management, always bearing in mind that any such therapeutic approach might face toxicity.
1. Introduction
1.1. Hepatic Fibrosis: Pathophysiology and Clinical
Importance. All hepatologists wish they had a crystal ball in
their clinic to enable them to determine whether or not their
immediate patient has liver fibrosis or not. This is because
liver fibrosis is a predominate key component of essentially
all chronic liver diseases. It is the formation of scar tissue in
response to parenchymal injuries such as chronic hepatitis
B (CHB) and C (CHC), nonalcoholic fatty liver disease
(NAFLD), or alcoholism (ALD). The continuous and pro-
gressive replacement of hepatocytes by the extracellular
matrix and fibrous tissue eventually leads to liver cirrhosis,
which in turn may lead to liver failure or promote a condu-
cive microenvironment for cancer development, in particular
hepatocellular carcinoma (HCC) [1, 2]. Whatever the etiol-
ogy of liver injury, it is the activation of hepatic stellate cells
(HSCs) that is responsible for liver fibrosis, being HSCs the
main collagen-producing cells in the damaged liver [3, 4].
HSCs transform during chronic liver injuries from a quies-
cent state into a myofibroblast-like phenotype (HSCs/MFBs),
which proliferate and migrate towards areas of necrosis and
regeneration [5, 6]. The main action of HSCs/MFBs consists
in a profound alteration of the extracellular matrix (ECM)
composition due to the upregulation of proteins such as α-
smooth muscle actin (α-SMA), interstitial collagens such as
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collagen 1A1, and matrix metalloproteinases (MMPs) such
as MMP9 as well as tissue inhibitors of metalloproteinases
(TIMPs), and proteoglycans. Activated HSCs also generate
hepatic cytokines such as transforming growth factor-β,
platelet-derived growth factor, connective tissue growth
factor, fibroblast growth factor, hepatocyte growth factor,
and vascular endothelial growth factor and recruit inflamma-
tory mono- and polymorphonuclear leukocytes that produce
chemokines, including monocyte chemotactic protein-
(MCP-) 1, regulated on activation normal T cell expressed
and secreted (RANTES), chemokine (C-C motif) ligand 21
(CCL21), and C-C chemokine receptor type 5 (CCR5).
Although HSCs’ critical role in liver fibrosis was proposed
nearly two decades ago [7], more recent data demonstrate
that, regardless of the underlying etiology of liver disease,
the majority of myofibroblasts comes from the liver-
resident HSC population [8]. While liver fibrosis was once
broadly thought of as an irreversible process, there is now
substantial evidence that, at least from a speculative point
of view, a near-normal hepatic architecture can be restored
upon cessation of injury [9]. However, these promising find-
ings must be offset by the fact that, after cessation of the
fibrotic triggering insult, around half of the activated HSCs
survive in an apparently quiescent state, as they are primed
to quickly reactivate into myofibroblasts in response to fibro-
genic stimuli [10, 11]. This leaves room for doubt that antifi-
brotic therapies meant to inhibit activated HSCs, although
beneficial to prevent ECM deposition, may be sufficient to
revert fibrosis permanently.
In any case, accurately defining the current fibrosis stage
reached by a patient along the course of his/her disease is, as
previously mentioned, of quintessential clinical importance,
since crucial decisions, such as starting monitoring for
complications (e.g., esophageal varices or HCC), depend on
it. Moreover, the presence and extent of liver fibrosis help to
predict prognosis and to prompt treatment decisions in vari-
ous chronic liver diseases. For instance, different international
treatment guidelines mention that the severity of liver fibrosis
should be considered, regardless of serum alanine aminotrans-
ferase level, for starting antiviral treatment for CHB [12, 13].
In conclusion, there are a multiplicity of reasons for which it
is crucial to diagnose and assess the extent of liver fibrosis.
1.2. Liver Biopsy for Staging of Fibrosis. Liver biopsy is still
considered as the gold standard method to assess liver fibrosis;
moreover, it provides useful information about diagnosis as
well as other damaging processes such as necrosis, inflamma-
tion, and steatosis [14]. All most widely usedmethods to assess
histological fibrosis are based on the description of the ele-
ments that mark the progression of the disease, such as peri-
portal fibrosis, septal fibrosis, and/or nodule formation [15].
One obvious and insurmountable limitation of liver
biopsy is that it is perceived as unduly invasive.
Furthermore, an insufficient sample size and divergence
based on differing experience among pathologists can lead
to significant interobserver disagreement. Risks associated
with liver biopsy include pain (84%), bleeding (0.5%),
damage to the biliary system (0.2%), and infections (0.1%),
with a mortality rate of approximately 0.01% [16]. Finally,
the cost of liver biopsy can be significant, leading to a ques-
tionable cost-effectiveness ratio [17].
1.3. Current Clinical Noninvasive Techniques to Assess
Hepatic Fibrosis. These limitations of liver biopsy have given
urgency for the development of alternative diagnostic proce-
dures for liver fibrosis. As a result, noninvasive techniques
have gained popularity in current clinical settings, leading
to a reduction of liver biopsies to stage the degree of liver
fibrosis; however, they also have several pitfalls.
The most traditional alternatives to invasive procedures
are represented by medical imaging. Ultrasonography, for
example, can suggest the presence of fibrosis and cirrhosis
but it is neither sensitive nor specific in its implementation,
performing positively only in late stages of liver cirrhosis,
when the signs of portal hypertension develop [18]. Com-
puted tomography and magnetic resonance are more sensi-
tive and specific but are burdened by the association of high
costs and inadequate interrater reliability among different
radiologists; moreover, the extensive use of computed
tomography scan is limited by radiological risks [19].
As a result, more innovative noninvasive approaches
have been (and are being) designed. The two principal
approaches that have been validated in large patient cohorts
with various etiologies are elastographic techniques measur-
ing liver stiffness and the detection and quantification of
serum markers.
Elastographic methods, which test liver stiffness, are rep-
resented mainly by transient elastography (FibroScan®).
Alternative techniques include point or multidimensional
shear wave elastography and magnetic resonance elastogra-
phy. All of these procedures, in addition to requiring expen-
sive equipment, may be inaccurate in obese or ascitic patients
and may lead to overestimation of fibrosis in patients with
high necroinflammatory activity [20]. Moreover, being the
result of the sum of inflammation and fibrosis in the liver
parenchyma, liver stiffness per semay not be the ideal candi-
date to monitor for fibrosis regression.
The advantages of biomarkers over liver biopsy, besides
being minimally invasive, are, at least from a speculative
point of view, their cost, ease of application, interlaboratory
reproducibility, and broad availability [21]. The rationale of
their use derives from the notorious ability of the liver to
either produce or modify a multiplicity of chemicals, a prop-
erty that has long been explored to estimate, from the
changes in their blood concentration, the degree to which
liver function is impaired and/or to which extent organ
damage is in addition to monitoring therapies. Indeed, liver
biochemistry panels (e.g., aminotransferases, alkaline phos-
phatase, γ-glutamyl transferase, bilirubin, albumin, and pro-
thrombin time) are included in almost all laboratory
routines, being informative, relatively cheap, and prone to
repeat testing [22]. Conceptually, fibrosis is of no exception.
By-products spilling in the blood as a result of the deposition
and removal of ECM produced by HSCs and other hepatic
cells can be taken as a proxy measure of what is occurring
in the liver parenchyma and are generally referred to as direct
markers of fibrosis (as opposed to the aforementioned
markers for liver injury which are considered indirect
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markers of the same). Typically, serum levels of the former
markers are elevated with progressing fibrosis and have a ten-
dency to decrease with response to treatment [23]. As a
result, their assessment may be useful for bringing about
effective treatment, but they are neither organ specific nor
readily available, unlike what would be required for an ideal
biomarker [21]. An exhaustive classification according to
their molecular structure can be found in a recent review
from Nallagangula et al. [24].
As a general rule, although a single direct marker may
serve as an indicator of disease severity, there is growing
consensus that a combination of multiple markers as an inte-
grated panel will enhance the performance characteristics in
terms of specificity and sensitivity. This is why patients can
now be profiled based on artificial intelligence algorithms
that produce scores by combining different biochemical
parameters (e.g., direct and/or indirect fibrosis markers
and/or blood platelet count), including, in some cases, demo-
graphics such as age or gender. Some of the main scoring
systems for liver fibrosis which have been implemented in
clinical practice include the aspartate aminotransferase-to-
platelet ratio (APRI) [25, 26], fibrosis- (FIB-) 4 [27], Fibro
index [28], Bonacini index [29], Forns test [30], and NAFLD
fibrosis score [31]. Unfortunately, none of these approaches
have produced highly accurate results for liver fibrosis
assessment to date [32] and their use in clinical practice
is not comparable to those of prognostic scores, such as
the Child-Pugh-Turcotte classification system [33] and
the Model for End-stage Liver Disease score [34]. In this
context, we also need to account for some derived scores,
such as FibroTest [35], Fibrometer [36], Hepascore [37],
and enhanced liver fibrosis [38], which include more specific
blood tests such as direct fibrosis markers (e.g., hyaluronic
acid [36–38], procollagen III amino terminal peptide [38],
and tissue inhibitor of metalloproteinase 1 [38]), that are
not routinely available. Again, the lines of evidence about
their reliability and cost-effectiveness are not sufficient to
support their use in clinical practice.
1.4. Evolving Biomarker Candidates for Liver Fibrosis. The
aforementioned limitations of most current surrogate
markers of liver fibrosis to provide stepwise follow-up
(meaning a sensitive and specific manner for the detection
and differentiation between the various stages of liver fibrosis
and the possibility to detect modest progression or regression
of fibrosis) explain why, on the one hand, liver biopsy has not
yet been abandoned and why, on the other, there is great cul-
tural eagerness to find new reliable noninvasive indicators,
also due to the putative treatments for liver fibrosis appearing
on the horizon. All newly discovered candidate markers may
therefore play a vital role in the assessment of chronic liver
injury which needs further evaluation. However, statistical
comparison should always be made with established bio-
markers and panels in large-scale multietiology validation
studies [24, 39].
Among the many new potential markers which are under
study, one of the most promising is represented by growth
arrest-specific gene 6 (Gas6) serum protein and its family of
receptors, namely, Tyro3, Axl, andMERTK (TAM). This sys-
tem has long been demonstrated to have a pivotal role in
fibrogenesis and in the progression of chronic liver diseases,
yet it is believed that we are currently verging on a break-
through in research due to the increasing knowledge of the
fine interplay of these factors with the various mechanisms
involved in liver damage. There is in fact a growing consent
on its potential use also as a useful novel biomarker for the
detection of liver fibrosis in vivo. However, many controver-
sies remain due to the complexity of the biological systems
involved.
The purpose of this work is to precisely review the litera-
ture data, highlighting the areas where the current lines of
evidence are more concrete and those that still need further
confirmation or validation.
2. Gas6/TAM Receptors
2.1. Biology of Gas6/TAM Receptors. TAM is one of the
twenty subfamilies of receptor tyrosine kinases [40].
Members of the TAM receptor family are Tyro3, Axl, and
myeloid-epithelial-reproductive tyrosine kinase (MERTK).
All comprise two immunoglobulin-like and two fibronectin
type III repeats in their extracellular domains in tandem.
These are connected to a single-pass transmembrane
domain and a cytoplasmic protein tyrosine kinase. Upon
ligand binding, the receptor dimerizes and the tyrosine
kinase becomes activated [41, 42]. TAM receptors differ
in the physiological tissue expression. Axl is expressed in
a wide variety of tissues and organs including the hippo-
campus, cerebellum, heart, skeletal muscle, liver, kidney,
testis, brain, monocytes, macrophages, platelets, endothelial
cells, and dendritic cell.
MERTK expression is found in the ovary, prostate, testis,
lung, retina, and kidney and macrophages, dendritic cells,
natural killer cells, megakaryocytes, and platelets. Tyro3 is
most prominent in the nervous system, but it is expressed
also in the ovaries, testis, breast, lung, kidney, osteoclasts, ret-
ina, monocytes/macrophages, and platelets [43]. Notewor-
thily, each receptor can be produced also as a soluble form
(sAxl/sMERTK/sTyro3) [44].
First cloned in 1991, TAM receptors were all considered
orphan receptors until 1995 [45]. In that year, their vitamin
K-dependent ligands, protein S and Gas6, were identified
[46–48]. While both Gas6 and protein S share common fea-
tures of domain organization and both require dimerization
and γ-carboxylation for their activity as TAM ligands, they
have differential specificities and affinities to TAM receptors
following their markedly different affinities. It is now gener-
ally accepted that Gas6 activates Axl, Tyro3, and MERTK
and that protein S activates MERTK and Tyro3. More in
detail, Axl is preferentially activated by Gas6 with 100–
1,000x higher binding affinity over Tyro3 and MERTK, sug-
gesting that it may be the most relevant of the three receptors
for Gas6 in many tissues, whereas affinity between protein S
and Axl has never been shown. MERTK displays lower sensi-
tivity to both ligands, and it is observed to have the greatest
phosphatidylserine (PS) dependence on ligand-induced acti-
vation. Tyro3 is preferentially activated by protein C. More-
over, Tyro3 and MERTK biological activation is enhanced
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in the presence of PS, implicating mainly both these receptors
in the clearance of apoptotic cells.
Whatever the receptor, in many cells, the activation of
TAMs is coupled with the downstream activation of the
phosphoinositide 3 kinase (PI3K)/AKT pathway. Most of
this downstream PI3K signaling is nucleated through a
TAM-autophosphorylated Grb2-binding site, which is
located 18 residues carboxy terminal to the kinase domain
and is conserved in all three TAMs. Coupling to phospholi-
pase C, ERK1/2, Ras, and MAP kinase activation have also
been described in many different cells [43, 49–51].
Coming back to the two TAM ligands, it is important to
note that they differ in tissue expression patterns. More in
detail, while natural anticoagulant protein S is mainly synthe-
sized in the liver, Gas6 is produced predominantly in the
heart, kidneys, and lungs and, to a lesser extent, in the liver.
Other important tissues where Gas6 is expressed are endo-
thelial cells [52], vascular smooth muscle cells [53], and bone
marrow [54]. Gas6 has also been shown to be present in
murine platelets, but this presence in humans has been
debated [55]. From a morphological point of view, the two
proteins share a high structural homology and sequence
identity. However, they have clearly different biological roles
[56, 57]. Protein S has mainly a TAM-independent inhibitory
effect on hemostasis [58–60]. The Gas6/TAM system has
instead clearly emerged from basic and clinical studies to
have rather pleiotropic effects with many biological func-
tions, sometimes playing more than one role at a time, as fre-
quently seen in human biology [61]. Specifically regarding
the area of coagulation, Gas6 seems to stimulate hemostasis
playing a complementary role in platelet function [62], and
it has been proposed as a biomarker for the diagnosis of pul-
monary embolism [63]. But, in recent years, several other sig-
naling functions of TAM receptors have been described, such
as stimulation of cell growth and proliferation, inhibition of
apoptosis [53, 64], mediation of efferocytosis (e.g., the pro-
cess by which dying cells are removed by phagocytes) [65],
and modulation of inflammation [66]. These effects probably
explain why the overexpression of TAMs (mostly Axl and
MERTK) can drive conventional oncogenic signaling and
survival pathways in different types of cancers, while also
playing an important role in epithelial to mesenchymal
transition and metastasis [42]. As a consequence, the overex-
pression of TAM receptors has been associated with che-
moresistance and poor survival outcomes [67].
A current research field that deserves a separate discus-
sion is the activity of Gas6/TAM on the immune system
[68]. Gas6 activation of the TAM receptors (specifically,
MERTK and Axl isolated from circulating monocytes and
tissue macrophages) was initially found to inhibit Toll-like
receptor (TLR) signaling, which in turn is a known trigger
of rapid inflammatory cytokine production in various cell
types [69]. Conversely, TLR signaling was demonstrated to
markedly decrease Gas6 expression in mouse macrophages
through the activation of the nuclear factor-κB, further facil-
itating—in a self-regulatory mechanism—the TLR-mediated
inflammation [70]. Furthermore, the Gas6/TAM system was
shown to be directly involved in the clearance of apoptotic
bodies [71]. As a matter of fact, Gas6 recognizes phosphati-
dylserine, a lipid normally expressed on the inner face of
the plasma membrane and exposed on the external mem-
brane during apoptosis, and bridges it with the TAM recep-
tors, driving macrophages to the recognition of apoptotic
cells and to their subsequent phagocytosis, stimulating natu-
ral killer cell development [72]. Other recent studies revealed
that Gas6/TAM signaling is involved in inflammation by
enhancing interactions between endothelial cells and leuko-
cytes [73]. Moreover, the induction of Axl limits cytokine
synthesis in activated monocytes or dendritic cells [74].
Based on these premises, it is not surprising that there has
been speculation on its possible role for the system in pre-
venting autoimmunity [75]. On the contrary, defects in
TAM signaling have been associated with numerous autoim-
mune diseases and degenerative diseases, since an impaired
clearance of apoptotic bodies and an inappropriate inflam-
matory response are considered critical for the deranged
immune response observed in these conditions. The role of
TAM receptors has been for instance studied in diseases such
as rheumatoid arthritis [76], multiple sclerosis [77–79], sys-
temic lupus erythematosus [80], Sjögren syndrome [81],
and Alzheimer’s disease [82].
The complexity of the crosstalk between Gas6 and its
receptors has increased to a further extent by the fact that
in many of the aforementioned diseases, such as rheumatoid
arthritis and lupus erythematosus, an impairment of the
physiological balance between the transmembrane and the
inactive soluble form of the receptors has been observed, sug-
gesting that an increased cleavage of the receptors could have
biological relevance in the pathogenesis of these conditions
[76, 83]. The most studied is probably sAxl. Physiologically,
Axl is cleaved by a disintegrin and metalloproteinase
(ADAM) 10 and 17 in a protein kinase C-dependent fashion
causing the release of sAxl which maintains the ability to
interact with Gas6 [84, 85]. Thus, the release of sAxl and its
involvement in a negative feedback loop by Gas6 binding
together with the γ-secretase-mediated release of a sAxl
intracellular domain (ICD) suggest bidirectional signaling.
2.2. Role of Gas6/TAM under Healthy and Pathological
Conditions in the Liver. In recent years, the Gas6/TAM inter-
action has been described to be relevant in inflammatory and
healing processes of the liver; in fact, Gas6 globally seems to
play a protective role in response to liver injury.
In the liver, Gas6 is mainly expressed in Kupffer cells with
levels below those observed in other tissues such as those
found in the lung, kidney, or heart [56]. However, after spe-
cific liver injury, other hepatic cell types may participate in its
production. For instance, Gas6 produced by HSCs together
with its receptor Axl participate in the signaling involved in
the injury repair mechanisms. Moreover, it has been shown
in animal models that Gas6 expression is also significantly
upregulated in injured areas by the other key cellular actors
involved after acute or chronic liver damage, such as macro-
phages, HSCs/MFBs, and liver progenitor cells (LPCs). In
this context, Gas6 exerts an antiapoptotic effect on both
HSCs and HSCs/MFBs, acting as a survival factor, probably
supporting transient HSC/MFB accumulation during liver
healing [86]. For instance, Gas6 produced by HSCs and
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infiltrating macrophages together with its receptor Axl par-
ticipate in the signaling (which includes, among others, the
aforementioned Axl/PI3K/AKT pathway) involved in the
wound healing response to liver injury by carbon tetrachlo-
ride (CCl4), and LPCs induce Gas6 production after hepatec-
tomy [86–88]. Moreover, an early increase in serum Gas6
levels has been demonstrated following liver ischemia/reper-
fusion (I/R) exposure [89].
Consistent with these findings, in Gas6−/− knockout
(KO) mice, abnormal wound healing after CCl4-induced
liver damage compared with wild-type animals has been
reported, with decreased expression of activation markers
for Kupffer cells (such as CD14, TNF-alpha, IL6, and MCP-
1) and HSCs (such as α-SMA and collagen type 1); as a con-
sequence, decreased macrophage and HSC/MFB recruitment
has also been shown in damaged areas. So Gas6 deficiency, by
limiting cytokine/chemokine release, prevents hepatocyte
proliferation, macrophage infiltration in liver necrotic areas
(which, in turn, is mediated by a direct chemotactic effect
of Gas6), and accumulation of myofibroblasts in healing
areas. Interestingly, in Gas6 KO mice, a positive feedback
on Axl expression was observed, with the concomitant
induction after CCl4 treatment of the suppressor of cytokine
signaling (SOCS) 1, suggesting that the delayed liver repair in
deficient mice may be a consequence of an inhibitory signal
arising from Axl receptor overexpression [88].
A similar mechanism probably explains what has been
described in hepatic I/R models. As already mentioned, in
mice following I/R exposure, an early increase in serum
Gas6 levels was reported. Unlike wild-type mice, Gas6-/-
mice were highly sensitive to partial hepatic I/R, with 90%
of mice dying within 12 hours of reperfusion due to massive
hepatocellular injury. I/R induced early hepatic AKT phos-
phorylation in wild-type but not in Gas6-/- mice, whereas
hepatic IL-1β and TNF mRNA levels (e.g., lipopolysaccha-
ride- (LPS-) induced cytokines) were higher in Gas6-/- mice
compared to wild-type mice. In line with the in vivo data,
in vitro studies indicated that Gas6 induced AKT phosphor-
ylation in primary mouse hepatocytes protecting them from
hypoxia-induced cell death, while Gas6 diminished IL-1β
and TNF in murine macrophages. Finally, the protective
role of Gas6 on cell growth and survival during tissue
repair was confirmed by the fact that in vivo recombinant
Gas6 treatment not only rescued Gas6 knockout mice from
I/R-induced severe liver damage but also attenuated hepatic
damage in wild-type mice following I/R. Thus, it may be
speculated that Gas6 could emerge as a potential therapeutic
target to reduce postischemic hepatic damage [89].
Synthesizing to the fullest extent, the protective role of
Gas6/TAM on the liver is mediated by its strong profibro-
genic potential. However, as in all biological processes, even
an initially favorable action—like a physiological reparative
process—can become, if out of control and especially if pro-
tracted in time, a factor of damage itself, since an excessive
fibrotic apposition in the liver can in turn become a patho-
physiological mechanism of hepatic injury. In this sense,
Gas6/TAM has a role like that of a “two-faced Janus,”
depending on clinical contexts. These concepts will be fur-
ther clarified in the following paragraphs.
2.3. Role of Gas6/TAM in Liver Fibrosis. The Gas6/TAM sys-
tem has recently emerged as an important player in progres-
sion to liver fibrosis through the aforementioned control of
inflammation and liver repair. Not surprisingly, the focus of
the few pathophysiological studies currently available is the
modulation of HSC activation, because of its recognized role
in the liver fibrosis associated to chronic liver injury of any
etiology, being HSCs the main collagen-producing cells in
any damaged liver [3, 4]. The most convincing study
comes from a murine model of Barcena et al. The authors
used both a genetic model of Axl deficiency (Axl KO) and
a pharmacologic approach, the Axl inhibitor BGB324.
HSCs were obtained from wild-type and Axl−/− mice,
treated with recombinant Gas6 protein (rGas6), Axl siRNAs,
or BGB324, and analyzed by western blot and real-time PCR.
Experimental fibrosis was then studied in CCl4-treated wild-
type and Axl−/−mice and in combination with Axl inhibitor.
After five weeks of CCl4 treatment, wild-type mice exhibited
a marked increase in Gas6 and sAxl serum levels compared
to controls, indicating that this pathway is upregulated dur-
ing CCl4-induced liver fibrosis. In primary mouse HSCs,
Gas6 and Axl levels paralleled HSC activation. rGas6 phos-
phorylated Axl and AKT prior to HSC phenotypic changes,
while Axl siRNA silencing reduced HSC activation. More-
over, BGB324 blocked Axl/AKT phosphorylation and dimin-
ished HSC activation. In addition, Axl KO mice displayed
decreased HSC activation in vitro and liver fibrogenesis after
chronic damage by CCl4 administration. Similarly, BGB324
reduced collagen deposition and CCl4-induced liver fibrosis
in mice [90].
Based on these premises, it is not hazardous to hypothe-
size that the Gas6/TAM systemmay have a prominent role in
the pathogenesis of major chronic liver diseases, with partic-
ular reference to fibrosis development. However, it must be
said that up to now the amount of evidence is still rather
scarce, and further clinical studies of adequate potency
are needed.
2.3.1. Gas6/TAM System and Nonalcoholic Fatty Liver
Disease. Taking into account the aforementioned limita-
tions, one of the most important liver disease models
which has been studied is NAFLD, which includes simple
nonalcoholic fatty liver and the more serious nonalcoholic
steatohepatitis (NASH). This nosological entity is one of
the leading causes of liver-related morbidity and mortality,
at least in developed Western countries. Whatever its eti-
ology, it is characterized by fat storage in hepatocytes, lob-
ular inflammation, elevated local and systemic cytokines,
activation of HSCs, and expansion of LPCs in periportal
areas, both in animal and human models [91, 92]. NAFLD
is a risk factor associated with toxic and metabolic fatty
liver disease and can progress to end-stage cirrhosis [93].
According to the two-hit model of NAFLD, steatosis is
the first hit that increases hepatocyte vulnerability to any
secondary insult eliciting an inflammatory response, but
most probably, both events are tightly interconnected since
fat accumulation per se induces oxidative injury and
inflammatory cytokine synthesis [94]. The persistent low-
grade inflammation due to chronic hepatocyte damage
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also plays a critical role in LPC expansion, which may play
a part in fibrosis [91, 92, 95, 96].
To address the role of Gas6 in NAFLD and in the pro-
gression to liver fibrosis, an animal model was studied, e.g.,
Gas6 KO mice fed with a choline-deficient ethionine-
supplemented diet (CDE) or receiving a CCl4 treatment
[97]. Gas6 deficiency attenuated hepatic steatosis by limiting
CDE-induced downregulation of genes involved in β-oxida-
tion observed in wild-type animals. Moreover, Gas6-
deficient mice displayed a reduction of hepatic inflammation,
revealed by limited F4/80-positive macrophage infiltration,
decreased expression of IL-1β, TNF-α, MCP-1, and lympho-
toxin-β, and attenuated LPC response to CDE diet. Gas6
deficiency moreover reduced CDE-induced fibrogenesis and
hepatic myofibroblast activation, decreased expression of
TGF-β and collagen type 1 mRNAs, and increased Axl pro-
tein levels. After chronic CCl4 injury, Gas6-deficient mice
also exhibited reduced liver fibrosis as a consequence of
defective macrophage recruitment compared with wild-type
animals. The authors concluded that the improvement of
steatohepatitis and fibrosis in Gas6−/− mice was linked to
an inhibition of the liver inflammatory response (similar to
other previously mentioned models) which in turn regulates
lipid metabolism and macrophage recruitment. Thus, this
study highlights the possible deleterious effect of Gas6 in
the progression of steatosis to steatohepatitis and fibrosis.
However, it has to be mentioned that in this CDE model no
induction of SOCS1 and 3 could be observed, as previously
observed in the CCl4 acute model of liver injury [98], thus
making the functional relevance of Axl overexpression in
Gas6-deficient mice still uncertain. Another possible weak-
ness of the work is that the other components of the TAM
family (e.g., Tyro3 andMERTK) were not tested, though they
may contribute to the Gas6 effects described in this NAFLD
animal model.
While, to the best of our knowledge, no current data are
available on Tyro3 role in NAFLD-related fibrogenesis
in vivo or in vitro, there are some pieces of evidence about
the pathophysiological role of Axl and MERTK.
For what concerns the former one, its distinctive subcel-
lular signaling during NASH development and the efficacy of
its intervention to prevent diet-induced liver fibrosis remain
to be explained. However, there are several preliminary
pieces of evidence that indicate that it may play an important
role in NAFLD progression. In particular, in a letter from
Mari et al., it is commented that increased Axl levels have
been detected in mouse models of NASH, anticipating a sig-
nificant role for Gas6/Axl in human NASH pathology [98].
These data were recently confirmed in a research from Tutu-
saus et al. in which it was described how Axl expression was
elevated in NAFLD patients and in mouse models of NASH.
Among individuals with different degrees of NAFLD (steato-
sis/fibrosis/cirrhosis), only cirrhotic patients displayed
increased Gas6 and MERTK serum levels. However, Axl
values were significantly elevated in all NASH groups in par-
allel to disease progression. Consistent with Axl influence in
HSC transdifferentiation, in human activated HSC cells
(LX2), the expression of profibrogenic genes after Axl activa-
tion was blocked by the selective Axl inhibitor BGB324. Axl
control of inflammatory response was then analyzed in acti-
vated human THP-1 macrophages.While Gas6 reduced LPS-
induced gene expression, Axl inhibition did not affect it.
Finally, mice fed with a high-fat diet choline-deficient with
methionine restriction (HFCD) developed significant hepatic
steatosis and fibrosis and exhibited increased sAxl levels,
recapitulating human NASH observations. Besides inhibiting
Axl, BGB324 administration increased circulating Gas6,
favoring Gas6 liver protection. This protective effect was con-
firmed also in HFCD-fed mice which showed reduced liver
fibrosis and hepatic inflammation. Taken together, these data
seem to suggest that sAxl levels are an early marker of NASH
that correlates with disease development and, at least in
experimental NASH models, that therapeutic inhibition of
Axl can diminish liver fibrosis by blocking HSC activation
and reducing hepatic inflammation, possibly due to Gas6
hepatoprotective action [99].
The other TAM receptor which has been studied in this
disease is MERTK. The latter one is a well-known key compo-
nent for the initiation of efferocytosis [42, 100] and is overex-
pressed in mouse HSCs activated by culture in plastic and in
experimental models of liver fibrosis (e.g., after induction of
chronic liver damage in response to CCl4 administration or
bile duct ligation) [90, 101]. Moreover, agonists of LXR, a
nuclear receptor favoring lipogenesis, increase MERTK
expression in monocytes [102]. Therefore, MERTK and its
variants could act as central players in the control of apoptosis,
immune response, HSC activation, and steatosis modulation,
e.g., all factors involved in the pathogenesis of NAFLD and
its fibrotic progression to steatohepatitis and cirrhosis. Based
on a genome-wide study in patients with CHC which,
amongst several susceptibility loci for severity and progression
of liver fibrosis, identified as the strongest one the homozygos-
ity for rs4374383 G>A single nucleotide polymorphism, a
non-coding variant in the MERTK gene [103], an in vivo
and in vitro study was conducted onNAFLD. In a large cohort
of patients with histological diagnosis of NAFLD, the protec-
tive AA genotype was associated with lower MERTK hepatic
expression (fibrosis F2-F4 in 19% of patients with MERTK
AA compared to 30% of those with MERTK GG/GA); the
AA genotype remained associated with clinically significant
fibrosis also at multiple logistic regression analysis. Similar
results were observed also when considering severe fibrosis
(F3-F4) as histological outcome. The prevalence of NAFLD
was not affected by MERTK genotype (39.7% in MERTK
AA vs. 44.1% in MERTK GG/GA), but severe steatosis was
observed in 8% of patients with MERTK AA compared with
21% with MERTK GG/GA genotype. Again, MERTK AA
genotype remained associated with severe steatosis at multiple
logistic regression. MERTK was overexpressed in the liver of
NAFLD patients with F2-F4 fibrosis, mainly in HSCs and
macrophages (but not in hepatocytes). Similarly, the receptor
was more represented in an animal model of fibrogenesis
(e.g., mice fed with a methionine- and choline-deficient diet).
Furthermore, the exposure of cultured human HSCs to
the MERTK ligand Gas6 increased cell activation and
migration and induced the expression of the profibrogenic
procollagen I. These effects were counteracted by the inhibi-
tion (both with specific small molecule inhibitor UNC569
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and siRNA) of MERTK activity, which also resulted in
apoptotic death of HSCs. The results of this research seem to
provide sufficient evidence for considering MERTK AA
genotype as an appealing new genetic biomarker in natural
history, pathophysiological, and interventional studies in
NAFLD [98, 104, 105].
2.3.2. Gas6/TAM System and Other Liver Diseases. Taking
into account other liver disease models, some preliminary
in vivo data are available for ALD and CHC infection. In
the previously mentioned Barcena et al. paper, the authors
recruited a small sample of patients (30 ALD, 51 CHC)
who all had hepatic fibrosis staged by liver biopsy. Addition-
ally, in both groups, patients were evenly distributed in
regard to the different degrees of liver disease, although in
the ALD group no moderate fibrosis cases (METAVIR F2-
F3) were included. Gas6 and sAxl serum levels were
measured before initiation of treatments. In ALD patients,
both an increase of Gas6 and sAxl were found in serum levels
of cirrhotic patients, showing close correlation to the severity
of the disease, although behaving differently. Specifically,
sAxl concentration had already augmented in individuals
with compensated cirrhosis compared to initial fibrosis,
while Gas6 levels had increased markedly in the decompen-
sated cirrhosis group. Moreover, a remarkable correlation
was found between the MELD score and both proteins. In
CHC patients, Gas6 levels were significantly different among
individuals with established fibrosis (F2) and patients with
initial fibrosis (F0 and F1 groups). In addition, F2 fibrosis
patients’ sAxl levels displayed significant changes in compar-
ison to individuals with advanced fibrosis or cirrhosis (F3/F4
group). The authors therefore could provide groundbreaking
evidence emphasizing for the first time the relevance of the
Gas6/Axl pathway also during the development of ALD-
and CHC-induced liver damage, supporting Gas6 and sAxl
serum levels as indicative parameters of hepatic dysfunction
and fibrosis development in liver disease and suggesting their
possible future prognostic role within a patient multidimen-
sional evaluation [90].
The report that sAxl levels are increased in advanced
fibrosis/cirrhosis has been confirmed in a much wider popu-
lation including 75 healthy controls, 400 chronic liver disease
patients of various etiologies (chronic viral hepatitis, autoim-
mune hepatitis, cholestatic liver disease, and NAFLD) and
fibrosis stages (including cirrhosis), and 347 HCC patients
[106]. For cirrhosis, sAxl showed a sensitivity of 80.8% and
a specificity of 92.0% at a cutoff of 54.0 ng/ml.
In any case, Axl is not the only component of the TAM
family which has demonstrated a putative role in hepatic
fibrosis progression. For instance, there are growing pieces
of evidence of MERTK involvement, at least for what con-
cerns CHC. More in detail, a genetic predisposition with
regard to an accelerated fibrosis (demonstrated by liver his-
tology and/or transient elastography) has been reported for
what concerns the aforementioned rs4374383 G>A single
nucleotide polymorphism. As shown in other diseases, it is
likely that patients carrying the GG/GA genotypes have a
significantly higher hepatic MERTK expression, although
the underlying mechanism is unknown [104]. This in turn
will lead to a dysregulation of the phagocytosis of apoptotic
cells by macrophages and, more in general, of various inflam-
matory responses [103, 107–109]. It has to be noted that,
although the rs4374383 SNP is not located in a regulatory
MERTK region, a high number of SNPs are in high linkage
disequilibrium (LD) with it. Thus, another SNP or SNPs in
high LD could be causally responsible. This issue was inves-
tigated by Cavalli et al., who suggested that rs6726639A allele,
in high LD with rs4374383 (r2 = 0 94), could promote the
binding of interferon regulatory factor 1 (IRF1) to this region
[110] and serve to activate or repress the expression of a high
number of genes involved in the immune response [111]. The
preferential binding of IRF1 to the A allele compared to
the C allele would downregulate MERTK in patients carry-
ing the A allele, protecting against CHC liver fibrosis and
HCC. So, in genetic association studies, the two SNPs
(rs4374383 and rs6726639) may be interchangeable for
predicting liver fibrosis progression.
The results of the aforementioned studies could leave
room to a possible future role for the targeting of TAM recep-
tors (e.g., with small molecule inhibitors against Axl or
MERTK) as a therapeutic strategy for liver fibrosis manage-
ment, with the caveat that any such therapeutic approach
might face toxicity. The measurement of the soluble levels
of Gas6 and its receptors (e.g., sAxl and sMERTK [102])
could furthermore be the basis of providing an easy and accu-
rate measurement of hepatic fibrosis progression, since
numerous other targets for antifibrotic agents are difficult
to be analyzed or to enter early-phase clinical studies due to
the lack of sensitive markers to follow the effects [90].
Returning to clinical studies whose purpose is to test the
role of plasma Gas6 as a novel putative biomarker of hepatic
fibrosis in different disease models, a paper from Bellan et al.
deserves a mention [112]. A fair number (113) of patients
were studied, the vast majority (81%) being affected by
CHC infection. Fibrosis was staged by transient elastography
and/or, whenever feasible and accepted, by liver biopsy;
again, all stages of hepatic disease were represented, from ini-
tial fibrosis to decompensated cirrhosis. Authors confirmed
Barcena’s finding that patients with histological demonstra-
tion of severe fibrosis had significantly higher Gas6 plasma
concentrations; they were also able to demonstrate for the
first time that Gas6 plasma concentration was directly corre-
lated to liver stiffness measured by transient elastography.
Even more relevant, the diagnostic accuracy of Gas6 was
comparable to that of liver elastography both in ruling out
and in detecting severe liver fibrosis. A proposed threshold
of 30 ng/ml for Gas6 plasma concentration was able to rule
out a clinically relevant degree of fibrosis with an 84% sensi-
tivity and 56% specificity, while values >42 ng/ml identified
severe fibrosis with a sensitivity of 64% and a specificity of
95%; however, taking into account that the majority of
patients was affected by chronic viral hepatitis, some caution
should be exercised before automatically generalizing these
conclusions when other conditions can be factors.
2.3.3. Gas6/TAM System: Does It Have a Role in Fibrosis
Complications? Of noteworthy importance, in the previously
reported paper from Bellan et al. [112], the authors noted a
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nonstatistically significant trend toward higher Gas6 concen-
trations in patients affected by cirrhosis complications (e.g.,
esophageal varices and HCC). These reports are to some
extent the expected consequence of the association with the
severity of fibrosis, since both conditions complicate the
natural history of cirrhosis. The former ones are the direct
consequence of a major hepatic fibrosis complication, e.g.,
portal hypertension.
The linkage with the latter is biologically more complex
to explain and also remains plausible for several relevant rea-
sons. The Gas6/Axl (both in transmembrane and soluble
forms) system has been, for instance, claimed to be con-
nected to the promotion of tumor invasion in various solid
malignancies, as recently confirmed in a meta-analysis
conducted on 3,344 total patients (379 with HCC) from 25
studies. Axl overexpression was significantly correlated with
poor prognosis (2.03-fold increase in mortality in all solid
tumor patients); in a subgroup analysis of different cancer
types, Axl overexpression was correlated with shorter overall
survival in a few tumors, including HCC (combined HR of
1.89 (95% CI 1.37–2.60, p < 0 001)) [113]. The pathophysio-
logical rationale of Gas6/Axl deleterious role probably
consists in its capacity to activate HSCs and modulate hepa-
tocyte differentiation, as suggested by a preliminary study
which demonstrated that in HCC cancer cell lines Gas6/Axl
can enhance cell invasiveness through transcriptional activa-
tion of Slug which induces epithelial to mesenchymal transi-
tion (EMT) [114]. Notably, under physiological conditions,
Gas6 and its receptor Axl are not expressed in hepatocytes.
However, Axl is strongly expressed in malignant hepatocytes
of about 40% of HCC patients showing progression towards
metastasis [115]. Moreover, as previously described in
immune stem and cancer cells, EMT-transformed hepato-
cytes upregulate the expression of Axl and secrete Gas6
revealing a possible autocrine/paracrine regulation loop in
the Gas6/Axl pathway [116]. In the background of fibrosis,
sinusoidal endothelial cells, activated HSCs, and Axl-
positive myofibroblasts as well as Kupffer cells release Gas6
into the tumor microenvironment of HCC, causing a Gas6-
enriched HCC stroma. These data suggest that Axl signaling
drives HCC progression in the presence of large amounts of
bioactive Gas6 and is of even more particular interest as tyro-
sine kinase inhibition is one of the most exploited antitu-
moral approaches of targeted therapies (e.g., bosutinib)
[114, 117, 118]. However, since very complex mechanisms
are involved that go extensively beyond the simple induction
of hepatic fibrosis, the precise analysis of the possible onco-
genic roles of the Gas6/TAM system in HCC signaling (in
many cases still lacking solid evidence) remains outside the
purpose of the present review.
A further analysis of the possible association of Gas6
plasma concentrations with the presence of esophageal vari-
ces comes from the same research group which extended the
abovementioned preliminary finding in a large cohort of
CHC-infected cirrhotic patients [119]. The clinical rationale
for such a research is that early detection of patients with var-
ices at high risk of bleeding (e.g., large varices) is crucial in
cirrhotic patients, but sparing endoscopy to low-risk patients
would be worthy of consideration. With this in mind, nonin-
vasive methods, such as Baveno VI criteria, have been pro-
posed to stratify the risk of esophageal varices (suggested
cutoffs for which screening for esophageal varices can be
safely omitted: liver stiffness at transient elastography < 20
kPa and a platelet count > 150 × 109/l) but unfortunately
have some limitations [120]. In the studied cohort, a total
of 74/160 (46%) patients had esophageal varices that were
large in 17/160 (11%) cases. 34/160 patients (21%) satisfied
Baveno VI criteria to avoid variceal screening, but one of
them had large varices at upper gastrointestinal endoscopy
(sensitivity 94%). Serum Gas6 values increased from
63ng/ml among patients without varices to 75 ng/ml among
patients with small varices and to 98 ng/ml among those with
large varices. A plasma Gas6 value < 45 ng/ml, detected in
34/160 (21%) patients, was 94% sensitive (but only 23% spe-
cific) in identifying patients without large varices; one of
these patients (different from the subject missed by
Baveno VI criteria) had large varices at upper gastrointes-
tinal endoscopy. The authors could then conclude that
plasma Gas6 concentration is a highly sensitive test to
identify patients with large varices, outperforming the
platelet count as a single biomarker of large varices and
proving to be comparable to the diagnostic performance
of Baveno VI criteria. This could provide the initial ratio-
nale for a future role for Gas6 in clinical settings in which
liver elastography is still not available or in those patients
for whom a reliable liver stiffness cannot be obtained (e.g.,
for ascites or morbid obesity).
For what concerns other severe complications of cirrho-
sis, e.g., portal hypertension-induced ascites, the role of other
TAM system members has been demonstrated, with particu-
lar regard to MERTK. This prorestorative marker shows a
two-faced activity: while for instance it is abundantly
expressed in liver macrophages during the resolution phases
of several diseases (e.g., acetaminophen-induced liver injury)
[121], it has also been identified as a potent suppressor of T
cell responses [122]. Regarding the latter activity, there are
for instance some pieces of evidence about the development
of immunoparesis in patients with acute on-chronic liver fail-
ure (ACLF) involving the unbalanced activation and overex-
pression of MERTK on monocytes/macrophages in the
circulation and tissue sites of inflammation [123–125]. The
great influence of MERTK-positive monocytes was con-
firmed in a late Antoniades work that studied ACLF patients
with ascites. Immunometabolic profiling of their ascites
revealed profound disturbances in myeloid cells with upreg-
ulated MERTK expression, impaired proinflammatory
responses to LPS, preferential lipid metabolism, and evidence
of epithelial cell death. The impact of these perturbations on
bacterial clearance could predispose to an increased suscepti-
bility to infections such as spontaneous bacterial peritonitis
(another severe complication of cirrhosis), but this still
requires further exploration [126].
Notably, coming back to HCC, some preliminary data
exist on a similar pattern of severe myeloid impairment. As
a matter of fact, in this tumor, it has been reported the expan-
sion of a MERTK-expressing immunosuppressive tumor-
associated macrophage population that suppresses host
innate and adaptive immune responses. In the same study,
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neoplastic patients, compared with controls, had also a sig-
nificant increase in MERTK-expressing circulating mono-
cytes (and in Gas6, as previously mentioned). Inhibition of
MERTK signaling restored their proinflammatory capabili-
ties, thereby identifying a possible novel immunotherapeutic
target in HCC [127].
2.3.4. Possible Implications of Soluble Axl in Liver Fibrosis. As
previously mentioned, Axl can be cleaved and released in
serum as sAxl. Since the latter is still able to bind Gas6 and
is therefore capable of depleting the ligand, it is considered
to be a critical determinant in affecting autocrine or paracrine
Axl signaling [128, 129]. Consequently, hepatic fibrosis pro-
gression should be subsequently attenuated by diminished
Gas6/Axl signaling, resulting in a phenotype comparable to
the one of chemically challenged Gas6 KO mice [97]. How-
ever, serum Gas6 levels have been shown to be elevated in
patients with advanced fibrosis and cirrhosis as well as in
HCC patients [85, 101]. Moreover, high Axl expression as
well as high sAxl levels independently correlate with fibro-
sis/cirrhosis [90, 106, 130]. These findings are contradictory
to the hypothesis that ectodomain shedding of Axl only leads
to signal dampening. There is in fact evidence that the ICD of
Axl could remain active supporting the belief of both a Gas6-
independent signaling, in parallel with a Gas6-dependent
one, which has been revealed by the previously mentioned
Gas6 KO and Axl KO studies showing reduced fibrogenesis
[90, 97]. This hypothesis is supported by the Holstein et al.
group that proposed there might be a switch predisposing
liver fibrosis, cirrhosis, or even HCC development, where
even in the event of a cleavage of Axl, the inhibitory Axl shed-
ding mechanism is circumvented due to the presence of
abundant nonshedded Axl receptors that will overcome the
loss of proteolytically cleaved Axl. Available free Gas6 is then
able to bind increasingly expressed Axl receptor and stimu-
late Gas6/Axl signaling driving fibrosis in the liver [117]. This
Gas6-independent signaling hypothesis implicates that pro-
teases are recruited to cleave the Axl ectodomain after
Gas6-mediated Axl activation. In this scenario, the ICD
could remain active and could still be able to phosphorylate
effector molecules [117]. However, it is an open question as
to whether ectodomain shedding occurs after Axl homodi-
merization and ICD activation. Interestingly, a mechanism
of shedding prior to receptor activation with ligand-
independent signaling has been reported for ErbB2 [131].
3. Conclusions
In the present paper, we have reviewed current evidence
regarding the use of Gas6 and its TAM receptors as potential
biomarkers of liver fibrosis.
The rationale for interest in Gas6 system derives from
the proven role of the Gas6 pathway in the HSC transdif-
ferentiation process from a normal vitamin A-storing to
an ECM-remodeling phenotype. This indeed is what ini-
tializes fibrosis. Despite recent progress in understanding
the biology of HSCs, the mechanisms are not yet fully
understood. In fact, in addition to the treatment/withdra-
wal of the underlying cause, fibrosis regression in chronic
liver diseases is not accomplished by any antifibrotic drug
despite the experimental description of an array of phar-
macological targets [3, 6]. Based on these premises, the
exact biological roles of Gas6 pathways, though undoubt-
edly relevant in human liver pathology, are still under
investigation at least in regard to the fibrogenesis process.
At any rate, what has clearly emerged from preclinical
and clinical studies is that Gas6/TAM is a profibrogenic
route. This means that it is beneficial/reparative in the
event of acute damage but profibrogenic/harmful if the
insult chronicizes. In this context, not only does the evidence
available so far make it interesting to test the potential use of
these system-related proteins as serological markers of dis-
ease progression/fibrosis but we may also speculate that this
pathway may provide a new therapeutic target not only for
liver fibrosis but also for different chronic liver diseases.
Moreover, the existence of specific inhibitors [132, 133],
already in clinical trials, may facilitate the biomedical transla-
tion of preclinical studies.
In the current state of the art, in essence, a sufficient
amount of data has now accumulated showing that Gas6
and its receptors, such as Axl and MERTK, play a relevant
role in the major models of chronic liver diseases. However,
reference has been limited to approximately a few hundred
patients tested in vivo. While results of the studies conducted
to date are promising, some major drawbacks remain. First,
to prove accurate staging of liver fibrosis by these novel sero-
logical markers, liver biopsies will still be needed to identify
the specific stage of fibrosis in each patient. The lack of such
material results in the usual incapacity of most studies to
report other facets of biomarkers beyond the ability to iden-
tify late stage fibrosis or cirrhosis, as compared to transient
elastography or validated serological scoring algorithms. Sec-
ond, large-scale multietiology validation of such novel serum
markers is still needed. The efficiency of the biomarkers
should be tested prospectively on large patient cohorts with
differences in age, gender, etiology of liver disease, etc. More-
over, it is reasonable that these novel biomarkers might find,
as many other noninvasive analytes, their best use within
more complex algorithms rather than in the simple measure-
ment of their plasma concentrations. For example, in the
paper from Barcena et al., an algorithm containing sAxl
and Gas6 could achieve an even stronger correlation
(r2 = 0 86) with the MELD score than the two analytes taken
individually, suggesting that the measurement of both pro-
teins provides a better evaluation of liver functionality [90].
Most likely, however, the best diagnostic solution will be
achieved combining these markers with more variables, not
necessarily directly related to the fibrosis itself. A first prelim-
inary confirmation comes from the work of Staufer et al. in
which sAxl performed better in predicting advanced liver
fibrosis (≥F2) when combined with serum albumin (in a sAx-
l/albumin ratio) in various chronic liver diseases [130].
Finally, the fine mechanisms of this like pleiotropic sys-
tem have still to be fully clarified. First of all, an important
issue about published data is that most have involved the
assay of single ligand against single TAM receptor. However,
some analysis has demonstrated that invalidation of one
TAM receptor might induce a compensatory enhancement
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of one or two other TAM receptors and also vice versa in the
case of upregulation of a single receptor [134, 135]. However,
the functional consequences of this reciprocal regulation
remain unclear. The complexity of Gas6/TAM system is also
revealed by what happens when it is the ligand (e.g., Gas6) to
be deficient. In these cases, a high and constitutive expression
of Axl is found, which reveals a negative control exerted by
Gas6 on its high-affinity Axl receptor expression. However,
the functional relevance of Axl overexpression, at least in
Gas6-deficient mice, is still uncertain and deserves further
studies [88, 97]. Another Axl negative feedback regulation,
which needs to be better clarified in liver pathology, involves
microRNA (miRNA). There are some preliminary data in
tumoral cells showing that miR-34a may target the 3′ UTR
of Axl mRNA to posttranscriptionally inhibit Axl expression,
modulating apoptosis in cancer cells, and revealing func-
tional implication of miRNA in the carcinogenic process.
On its turn, Axl overexpression may induce miR-34a expres-
sion [136]. Obviously, also many positive feedbacks regulate
Gas6/TAM system. There is for instance an interesting recent
report that again needs to be validated in hepatic diseases
about a novel oncogenic long noncoding antisense RNA
(Gas6-AS1) that can control the expression of its cognate
sense gene Gas6 at the transcriptional or translational levels.
Its net effects consist in supporting tumor progression via
inducing an increase of Axl levels and driveling Axl signaling
pathway activation [137]. Another partially unresolved issue
concerning Gas6/TAMs is, as previously mentioned, whether
the shedding of activated Axl receptors could lead to Gas6-
independent signaling, with potential consequences not only
on fibrogenesis but also on hepatic oncogenesis [117]. Other
issues which need further investigation concern the other
relevant TAM receptor in liver pathology, e.g., MERTK. As
a matter of fact, it still has to be resolved the particular con-
tribution of sMERTK to hepatic inflammation and fibrogen-
esis. It is believed, like other soluble TAM receptors, to
compete with the bound receptors and thus inhibit their
function. In other chronic disease models, significantly lower
expression of MERTK in monocytes has been described;
conversely, sMERTK expression was increased compared to
controls and related to disease severity. Moreover, the metal-
loproteinase ADAM 17, responsible for cleavage of MERTK
to its soluble form, has been shown to be increased in patient
monocytes [138]. These observations suggest that functional
deficiency of TAM receptor-mediated regulation of inflam-
mation may contribute to chronic inflammation and, trans-
lating this to liver physiopathology, be a potential driver of
fibrosis progression. It would then be interesting to evaluate
if sMERTK levels are altered in patients with steatohepatitis
or viral infection. However, additional aspects of MERTK
liver biology deserve, in our opinion, to be further analyzed.
For example, future research should verify if MERTK inhi-
bition or MERTK KO mice display reduced fibrosis, as
already observed in Axl KO mice or after pharmacological
Axl inhibition [90].
In conclusion, in the foreseeable future, Gas6/TAM
receptors have a strong pathophysiological rationale and
a potential use as serological markers of disease progres-
sion in chronic liver diseases; moreover, the system may
be targeted in future liver therapies (e.g., in clinical trials
testing small molecule inhibitors). If these tools were to
be further optimized by improving their accuracy, while
at the same time handling other possible confounding
factors, their presence in a liver clinic may provide a
means for making the correct diagnosis, analogous to hav-
ing a much longed for crystal ball.
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